See more : Jana Small Finance Bank Limited (JSFB.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Silo Pharma, Inc. (SILO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silo Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TIS Inc. (3626.T) Income Statement Analysis – Financial Results
- MGI Digital Technology Société Anonyme (ALMDG.PA) Income Statement Analysis – Financial Results
- Triumph Gold Corp. (TIGCF) Income Statement Analysis – Financial Results
- Jiangyin Jianghua Microelectronics Materials Co., Ltd (603078.SS) Income Statement Analysis – Financial Results
- Tate & Lyle plc (TATYF) Income Statement Analysis – Financial Results
Silo Pharma, Inc. (SILO)
About Silo Pharma, Inc.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.10K | 72.10K | 71.26K | 40.92K | 40.57K | 0.00 | 847.41K | -669.48K | -145.19K | -107.11K | 105.52K | 0.00 | 0.00 |
| Cost of Revenue | 5.84K | 5.84K | 5.00K | 176.13K | 27.39K | 17.55K | 0.00 | 0.00 | 0.00 | -127.68K | 104.90K | 0.00 | 0.00 |
| Gross Profit | 66.26K | 66.26K | 66.26K | -135.20K | 13.18K | -17.55K | 847.41K | -669.48K | -145.19K | 20.57K | 625.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 91.90% | 91.90% | 92.98% | -330.38% | 32.49% | 0.00% | 100.00% | 100.00% | 100.00% | -19.20% | 0.59% | 0.00% | 0.00% |
| Research & Development | 845.09K | 1.29M | 693.91K | 88.80K | 63.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Selling & Marketing | 0.00 | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.70K | 269.44K | 72.61K | 39.45K | 49.80K |
| Other Expenses | 0.00 | 2.17M | 1.95M | 3.00K | 765.72K | 314.61K | 177.50K | 142.50K | 96.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.92M | 3.71M | 2.96M | 2.27M | 927.65K | 459.83K | 490.87K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Cost & Expenses | 3.93M | 3.72M | 2.96M | 2.45M | 955.03K | 459.83K | 427.96K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.80K |
| Interest Income | 398.53K | 72.64K | 1.21K | 11.54K | 12.20K | 4.22K | 20.48K | 49.84K | 40.34K | 20.57K | 625.00 | 0.00 | 0.00 |
| Interest Expense | 4.87K | 2.20K | 3.04K | 269.27K | 62.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 72.64K | -147.29K | 179.92K | 28.14K | 17.55K | -701.10K | 719.32K | 192.33K | 127.68K | -104.90K | 0.00 | 0.00 |
| EBITDA | -3.63M | -3.91M | 4.19M | -2.39M | -930.40K | -951.91K | 0.00 | 0.00 | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| EBITDA Ratio | -5,029.28% | -4,958.28% | -4,057.63% | -5,847.68% | -2,224.03% | 0.00% | -138.24% | -48.64% | 17.11% | 113.14% | -167.63% | 0.00% | 0.00% |
| Operating Income | -3.86M | -3.65M | -2.74M | -2.57M | -930.40K | -594.24K | -470.39K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.80K |
| Operating Income Ratio | -5,347.41% | -5,059.02% | -3,850.95% | -6,287.34% | -2,293.38% | 0.00% | -55.51% | 58.80% | 149.58% | 232.34% | -68.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 224.51K | -279.73K | 6.93M | -464.55K | -82.89K | -375.22K | 826.92K | -719.32K | -192.33K | 0.00 | 104.90K | 0.00 | 0.00 |
| Income Before Tax | -3.63M | -3.91M | 4.18M | -3.04M | -1.01M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Income Before Tax Ratio | -5,036.04% | -5,419.25% | 5,868.30% | -7,422.52% | -2,497.71% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.16K | 24.88K | 92.35K | 34.79K | -513.85K | -62.91K | 696.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -3.70M | -3.91M | 3.90M | -3.13M | -1.05M | -969.46K | 356.54K | -1.11M | -409.50K | -376.55K | 32.91K | -39.45K | -49.80K |
| Net Income Ratio | -5,132.57% | -5,420.86% | 5,477.86% | -7,648.18% | -2,583.47% | 0.00% | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | 0.00% | 0.00% |
| EPS | -1.20 | -1.71 | 2.06 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| EPS Diluted | -1.20 | -1.71 | 2.03 | -2.37 | -1.24 | -0.99 | 0.50 | -1.11 | -0.40 | -0.39 | 0.05 | -0.06 | -0.08 |
| Weighted Avg Shares Out | 3.08M | 2.28M | 1.90M | 1.32M | 842.30K | 982.03K | 1.00M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.28M | 1.92M | 1.32M | 842.30K | 982.03K | 1.04M | 1.00M | 1.01M | 958.30K | 648.74K | 612.62K | 612.62K |
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery...
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel...
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company...
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and...
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
Presentation to feature Silo's novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems...
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the...
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that...
Why Is Silo Pharma (SILO) Stock Up 60% Today?
Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ: SILO ) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop...
Source: https://incomestatements.info
Category: Stock Reports